EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial

Kozo Kataoka iD, Takeshi Yamada iD, Kentaro Yamazaki, Shintaro Kanaka, Takeshi Suto, Manabu Shiozawa, Yasumasa Takii, Masayoshi Yasui iD, Toshifumi Yamaguchi, Nobuhisa Matsuhashi, Naoto Takase, Kazuma Ito und 11 weitere

BJS Open · 03.11.2026 · 10 (6)

DOI: 10.1093/bjsopen/zrag144 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift BJS Open, online erschienen am 04.11.2026. Verfasst von Kozo Kataoka und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Lower Gastrointestinal Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Camptothecin. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japanese Society of Clinical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with oligometastatic colorectal cancer (mCRC) remain at high risk of recurrence after curative surgery, yet the benefit of adjuvant chemotherapy remains inconclusive. This study evaluated the feasibility and efficacy of adjuvant modified (m)FOLFOXIRI (irinotecan, oxaliplatin, L-leucovorin (L-LV), 5-fluorouracil (5-FU)), as well as the utility of circulating tumour DNA (ctDNA) as a prognostic and predictive biomarker in mCRC.

Methods

Between October 2020 and January 2024, patients with histologically confirmed mCRC undergoing complete metastasectomy were enrolled in this multicentre non-randomized phase II study. Eligible and consenting patients received eight cycles of mFOLFOXIRI followed by four cycles of 5-FU/L-LV; ineligible/non-consenting patients received standard of care (SOC; CAPOX (capecitabine and oxaliplatin), 5-FU, or observation). ctDNA was assessed using the tumour-informed personalized Signatera™ assay (Natera, Austin, TX, USA) at 28 days and 7 months after surgery. The primary endpoint was completion of eight cycles of mFOLFOXIRI in a target sample of 36 patients.

Results

Of the 83 registered patients, 73 were enrolled (39 mFOLFOXIRI, 34 SOC). The mFOLFOXIRI completion rate was 74% (80% confidence interval 63% to 83%; P < 0.001). ctDNA positivity predicted significantly inferior recurrence-free survival across both the mFOLFOXIRI and SOC treatment groups at 28 days (hazard ratios (HR) 7.27 and 7.17, respectively) and 7 months (HR 3.96 and 4.38, respectively) after surgery. Multivariate analysis identified ctDNA positivity, RAS mutation, metachronous metastases, and mFOLFOXIRI as significant prognostic factors. mFOLFOXIRI improved recurrence-free survival compared with SOC in the overall population (HR 0.44; P = 0.012), with a trend towards benefit in ctDNA-positive but not ctDNA-negative patients. ctDNA clearance rates were 33% (mFOLFOXIRI) and 20% (SOC).

Conclusions

This study indicates the feasibility of adjuvant mFOLFOXIRI in patients with mCRC, with an acceptable safety profile and potential clinical benefit among those with ctDNA positivity 28 days after surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCamptothecinHumansFemaleLeucovorinFluorouracilChemotherapy, AdjuvantMaleAgedOrganoplatinum CompoundsMiddle AgedCirculating Tumor DNANeoplasm Recurrence, LocalIrinotecanMetastasectomyOxaliplatinPrognosisNeoplasm MetastasisAdult

Stichwörter der Autor:innen

circulating tumour DNAminimal residual diseaseoligometastatic disease

Substanzen

LeucovorinFluorouracilOrganoplatinum CompoundsCirculating Tumor DNAIrinotecanCamptothecinOxaliplatin

Autor:innen und Institutionen

  • Division of Lower Gastrointestinal Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
  • Department of Gastrointestinal Surgery, Nippon Medical School, Tokyo, Japan.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Japan.
  • Department of Gastrointestinal Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
  • Department of Surgery, Niigata Cancer Center Hospital, Niigata, Japan.

ORCID-Profile: Kozo Kataoka, Takeshi Yamada, Masayoshi Yasui, Erik Spickard, Rama S Madhurapantula, Eiji Oki, Hideaki Bando, Takayuki Yoshino, Yukihide Kanemitsu

Förderung

  • Japanese Society of Clinical Oncology

Zitieren

APA

Kataoka, K., Yamada, T., Yamazaki, K., Kanaka, S., Suto, T., Shiozawa, M., Takii, Y., Yasui, M., Yamaguchi, T., Matsuhashi, N., Takase, N., Ito, K., Spickard, E., Fungtammasan, A., Madhurapantula, R. S., Jurdi, A., Oki, E., Bando, H., Nakamura, Y., …, & Kanemitsu, Y. (2026). Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial. BJS Open, 10(6). https://doi.org/10.1093/bjsopen/zrag144

Vancouver

Kataoka K, Yamada T, Yamazaki K, Kanaka S, Suto T, Shiozawa M, et al. Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial. BJS Open. 2026;10(6). doi:10.1093/bjsopen/zrag144

BibTeX
@article{Kataoka2026,
  author = {Kataoka, Kozo and Yamada, Takeshi and Yamazaki, Kentaro and Kanaka, Shintaro and Suto, Takeshi and Shiozawa, Manabu and Takii, Yasumasa and Yasui, Masayoshi and Yamaguchi, Toshifumi and Matsuhashi, Nobuhisa and Takase, Naoto and Ito, Kazuma and Spickard, Erik and Fungtammasan, Arkarachai and Madhurapantula, Rama S and Jurdi, Adham and Oki, Eiji and Bando, Hideaki and Nakamura, Yoshiaki and Yoshino, Takayuki and Ikeda, Masataka and Mori, Keita and Kanemitsu, Yukihide},
  title = {Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial},
  journal = {BJS Open},
  year = {2026},
  volume = {10},
  number = {6},
  doi = {10.1093/bjsopen/zrag144}
}
Kostenlos starten →